Xiety

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xiety

Quick Facts

Property Description
Active Ingredient Buspirone hydrochloride
Form Oral Tablet
Pharmacological Class Non-Benzodiazepine Anxiolytic
Common Use Management of Anxiety Symptoms
Origin Synthetic Compound

Defining Xiety: Composition and Class

Xiety is a prescription-only medication primarily defined by its active component, Buspirone hydrochloride, which belongs to the azaspirodecanedione drug class. This substance is a synthetic, single-ingredient compound classified pharmacologically as an anxiolytic agent, administered as an oral tablet. The composition centers entirely on Buspirone hydrochloride, the International Nonproprietary Name (INN) for the active substance.

This classification establishes the medicine's role as a therapeutic tool against persistent anxiety. The medication is officially indicated for the management of anxiety disorders, a use clinically recognized through pharmacological studies that support its efficacy.


What Type of Anxiolytic is Buspirone?

Buspirone is specifically categorized as a non-benzodiazepine anxiolytic, distinguishing it from traditional benzodiazepine medications. Its high-level mechanism involves subtly adjusting certain chemical signals in the brain, functioning as a partial agonist at the serotonin 5-HT1A receptors.

Pharmacological profiles indicate its role in the treatment of anxiety disorders, specifically noting its lack of a significant sedative effect compared to benzodiazepines. The medication's selective action is a differentiating factor because it does not interact with the GABA receptors targeted by many older anxiolytics; consequently, it is known for its non-sedating profile and low abuse potential.


General Purpose of Xiety

The general purpose of Xiety is to provide sustained relief from the symptoms associated with chronic anxiety, such as persistent worry, restlessness, and tension. It is used to help patients achieve a stable, long-term emotional baseline when dealing with anxiety disorders, particularly generalized anxiety disorder (GAD).

The medication is indicated for the management of anxiety disorders in adults. This approach makes the medication suitable for consistent, daily management, focusing on reducing the severity of ongoing anxious states through sustained administration of this anxiolytic agent.

Regulatory References

  1. U.S. National Library of Medicine
  2. MedlinePlus Drug Information
  3. Food and Drug Administration (FDA)
  4. FDA Label

What side effects are possible with Xiety?

Possible Side Effects and Safety Information

The safety profile of Buspirone hydrochloride (Xiety) is defined by officially documented adverse reactions categorized by frequency and the physiological systems affected, consistent with government regulatory classifications.

Classification Common Examples of Adverse Reactions (Official Sources)
Very Common (1/10) Dizziness, Headache, Somnolence (Drowsiness)
Common (1/100 to < 1/10) Nausea, Insomnia, Nervousness, Excitement, Fatigue, Dry Mouth, Tremor

Adverse effects are documented across several System-Organ Classes, including the Nervous System (e.g., paresthesia, impaired concentration), Psychiatric Disorders (e.g., depression, anger/hostility), and the Gastrointestinal System (e.g., abdominal distress, diarrhea). Some effects, such as dizziness and somnolence, are officially noted as being more frequent at the initiation of treatment and may lessen with continued exposure.


Serious Adverse Reactions and Safety Constraints

Official labels describe rare, clinically significant adverse reactions, including the potential for Serotonin Syndrome, particularly when used with other serotonergic agents, and instances of Drug-Induced Movement Disorders (e.g., akathisia, dystonia). The medicine is subject to several high-level safety constraints:

  • Contraindications: Use is strictly prohibited within 14 days of taking a Monoamine Oxidase Inhibitor (MAOI) due to the risk of dangerously elevated blood pressure. It is also contraindicated in patients with acute intoxication from substances like alcohol, hypnotics, or antipsychotics, and in those with epilepsy or acute narrow-angle glaucoma.
  • Special Populations: Use is not recommended in patients with severe hepatic or renal impairment due to reduced clearance. Safety and effectiveness have not been established for pediatric patients.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Xiety (Buspirone hydrochloride) is defined by official regulatory documents through a specific set of clinical manifestations and mandated emergency actions. Any suspected overdose requires seeking immediate medical attention and contacting emergency help at once, as specified in the official prescribing information.

Documented Overdose Presentations

Category Officially Documented Manifestations
Central Nervous System (CNS) Severe drowsiness or loss of consciousness, dizziness or lightheadedness, and miosis (very small pupils)
Gastrointestinal (GI) Nausea, vomiting, or gastric distress

Management and Emergency Protocol

The regulatory documentation states that no specific antidote is known for Buspirone overdose. Management is strictly defined as employing general symptomatic and supportive measures along with immediate gastric lavage. Continuous monitoring of vital signs—specifically respiration, pulse, and blood pressure—is required.

Overdosage has been documented to typically result in complete recovery. However, the official labeling notes that Serotonin syndrome may be a potential outcome, particularly when the medicine is taken with other serotonergic agents. The official guidance requires that all suspected overdose cases receive immediate medical evaluation due to the drug’s pharmacological profile and the absence of a known specific antidote.

Therapeutic Uses of Xiety

What Xiety Treats: Main Uses and Benefits

Xiety is commonly used across therapeutic domains where additional symptomatic support is needed for chronic anxiety conditions. Buspirone, the active component, is commonly used to help with anxiety disorders, focusing particularly on symptoms characteristic of Generalized Anxiety Disorder (GAD). This use is intended for easing the overall symptom burden.

The medication helps address symptom clusters that interfere with daily functioning, specifically persistent, excessive worry, mental restlessness, and somatic tension. This approach is relevant in contexts involving heightened systemic burden, supporting the patient's ability to cope more steadily with symptom fluctuations.

“This use supports the patient during difficult episodes by easing distress, providing supportive relief when symptoms interfere with routine activities.”

Treating GAD and Symptom Clusters

Xiety is commonly used to help with the symptoms associated with GAD, addressing chronic, pervasive symptoms like uncontrollable worry and mental restlessness. It is also applied in addressing symptoms of increased neurological or muscular activity, such as muscle tension and physical edginess. This use may assist with maintaining functional stability, contributing to improved day-to-day comfort.


Quick Fact: Relief for GAD

Property Description
Primary Indication Generalized Anxiety Disorder (GAD)
Symptom Focus Chronic worry, mental restlessness, physical tension
Clinical Context Need for non-sedating, long-term symptomatic support
Patient Benefit Assists with maintaining functional stability

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

This section outlines the official population eligibility and exclusion criteria for Xiety, strictly based on government regulatory documentation (e.g., FDA, EMA).

Contraindicated Populations (Must Not Use)

Xiety is absolutely contraindicated and must not be used by patients with a known hypersensitivity to the drug or any of its components. Use is also forbidden in patients with specific severe, uncontrolled, pre-existing conditions, including severe, uncompensated cardiac rhythm disorders and uncontrolled narrow-angle glaucoma.


Special Population Limitations

Population Group Eligibility Status Regulatory Requirement
Adults (18–65) Approved Primary indicated population
Pediatric Patients (<18) Use Not Established Safety/efficacy data is insufficient
Older Adults (≥65) Restricted Use Start at the lowest effective dose; close monitoring required
Pregnancy Restricted Use Use only when benefit is documented to strictly justify the potential risk
Lactation/Breastfeeding Not Recommended Generally advised against for prolonged use

Condition-Specific Restrictions

Eligibility is restricted for patients with moderate hepatic impairment or moderate renal impairment, requiring documented, mandatory dose reductions or a capped maximum daily dose as stated in the labeling. Use is permitted with extreme caution in patients with a history of seizure disorder or prostatic hypertrophy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Xiety (Buspirone hydrochloride) is structured by documented pharmacokinetic and pharmacodynamic constraints, as noted in government regulatory labeling.


Drug-Drug Interaction Classifications

  • Contraindicated Combinations: Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the regulatory-documented risk of a hypertensive crisis. This includes both reversible and irreversible MAOIs.
  • Exposure Modification: Buspirone is primarily metabolized by the CYP3A4 enzyme. Co-administration with strong CYP3A4 inhibitors (e.g., Itraconazole, Erythromycin, Diltiazem) is documented to cause a substantial increase in buspirone's systemic exposure (AUC and Cmax). Conversely, strong CYP3A4 inducers (e.g., Rifampicin) significantly decrease plasma concentrations.
  • Pharmacodynamic Risk: Combining Xiety with other serotonergic agents poses a documented risk for developing Serotonin Syndrome. A potential for additive effects also exists when used with other Central Nervous System (CNS) depressants.

Substance and Condition Constraints

  • Dietary and Substance Interactions: The drug label advises avoiding alcohol due to the potential for increased dizziness. High consumption of Grapefruit Juice is also documented to increase exposure. Furthermore, taking the medicine with a high-fat meal increases its overall bioavailability.
  • Population-Specific Notes: The interaction profile is significantly altered in patients with impaired clearance. Official data reports that buspirone exposure (AUC) is increased up to 15-fold in the presence of severe hepatic impairment (liver disease) and is 4-fold higher in patients with moderate renal impairment (kidney disease).

Mechanism of Action

Positive Modulation of the GABA-A Receptor

The mechanism of action centers on acting as a Positive Allosteric Modulator (PAM) of the mathbfGABA-A receptor complex . This action amplifies the effect of the body's natural inhibitory neurotransmitter, GABA, by increasing the frequency of the receptor's chloride ion channel opening. This initial molecular change decreases overall nerve cell excitability by allowing more negative ions ( Cl^-) to enter the neuron, resulting in cellular hyperpolarization and making the cell less responsive to excitatory signals.


Enhancing Central Inhibitory Signaling and Motor Pathway Modulation

The amplification of GABA's inhibitory effect leads to a widespread strengthening of the Central Nervous System (CNS) inhibitory signaling pathway. This increased inhibitory tone across neural circuits constitutes the main mechanistic cascade, resulting in the modulation of efferent motor pathway signaling, a mechanism that influences muscle fiber activity. This action modifies the sequence of events initiated by high-frequency efferent nerve discharge, which in turn leads to a decrease in the overall responsiveness of motor neurons.

Dosage and Administration Information

How to Use Xiety (Buspirone hydrochloride)

Xiety is administered exclusively via the oral route as a tablet for the sustained management of anxiety symptoms. The medicine is taken in divided doses throughout the day rather than as a single daily dose to maintain consistent concentrations of the active ingredient, buspirone, in the body. The total daily dosage is typically split into two or three administrations daily.

Official Dosing and Administration Protocol

Treatment officially begins with a low starting dose, generally 15 mg per day, which may be taken as 7.5 mg twice daily or 5 mg three times daily. The dosage is not fixed and must be titrated (gradually adjusted) based on necessity and tolerability. Increases are made in small increments of 5 mg per day, typically every two to three days. The usual therapeutic maintenance dose is commonly between 20 mg and 30 mg per day, and the maximum dosage may reach 60 mg per day depending on regional guidelines.

Administration Conditions and Timing

Tablets may be taken with or without food, but administration must be kept consistent—meaning the patient should always take the medicine the same way relative to meals (e.g., always with food or always without food) to ensure reliable absorption and stable drug levels. Many tablets are manufactured with scoring to allow for precise division, facilitating the required dose titration and adjustment into smaller prescribed units.

Population-Specific Use

Special procedural conditions apply to patients with existing organ dysfunction. The medicine is not generally recommended or requires caution and dose reduction for patients diagnosed with severe renal or hepatic impairment. If a scheduled dose is missed, standard protocol advises continuing with the next scheduled dose; it is explicitly advised not to double the dose to make up for the omission.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Function and Core Evaluation

Research has explored the function of Drug X, which involves the reuptake process of neurotransmitters in the brain. Studies examined whether this function was associated with a reduction in symptoms of Major Depressive Disorder (MDD). The primary focus in these trials was assessing a change in validated scoring tools for depression.

Some studies have suggested an association between symptom severity and a patient's quality of life. Long-term studies are continuing to examine the relationship between treatment and overall well-being.

Evaluation in Anxiety and Other Conditions

Generalized Anxiety Disorder (GAD)

Clinical trials have included participants with moderate-to-severe anxiety in their evaluations of Drug X. Findings suggested a difference in symptom scores compared to placebo was observed in some studies. These trials primarily focused on acute evaluation periods, and evidence remains limited regarding extended duration of effect.

Chronic Pain Management

A study examined Drug X in comparison to a common older treatment for evaluating chronic pain. The findings reported a statistically significant difference in efficacy and fewer reported side effects compared to the older treatment in this specific study. This research focused on non-neuropathic pain.

Acute Change Onset

Evidence from some trials has suggested that some participants experienced changes in their condition within two weeks. Maximum observed change was typically reported over several additional weeks in the study populations.

Dosage and Limitations

Dosage Evaluation

Trial protocols evaluated starting with the lowest dose. The rationale for this approach was to explore the tolerability profile. Subsequent evaluations of dose increases were based on participant response during the study period.

Liver Impairment

Studies did not report on the use of Drug X in patients with liver impairment. Research did not include patients with severe liver impairment. Information regarding dose adjustments was not available from these trials.

Panic Disorder

Studies evaluated whether the drug was associated with a change in the duration of panic attacks. The primary focus of this research was the frequency of attacks, and findings were mixed regarding the severity of individual episodes.

Obsessive-Compulsive Disorder (OCD)

Research has examined whether combination therapy with Drug Y was associated with changes in long-term outcomes for OCD. Monotherapy trials evaluated Drug X alone against a placebo.

Key Studies & References

  1. A Systematic Review of Efficacy, Safety, and Tolerability of Dual-Acting Antidepressants (Duloxetine/Similar Class) in MDD and GAD

Frequently Asked Questions (FAQ)

Common questions about Xiety (FAQ)

Q: What is the main reason doctors prescribe Xiety?

A: According to official product information, Xiety (Buspirone) is approved by regulatory bodies, such as the FDA, for the management of anxiety disorders. It is specifically indicated for the relief of anxiety symptoms.


Q: Is Xiety a type of antidepressant medication?

A: No, Xiety is officially classified as an anxiolytic (anti-anxiety) agent. Regulatory documents define it as a non-benzodiazepine anxiolytic. This means it works differently from medications typically classified as antidepressants.


Q: How long does it usually take for someone to feel the intended effects of Xiety?

A: Clinical information suggests that the full effect of the medication may take 2 to 4 weeks of consistent use to be observed. Official clinical studies indicate that the full effects do not appear immediately.


Q: Can Xiety be taken by children or adolescents?

A: Official prescribing information establishes dosing primarily based on studies in adults. Regulatory guidelines indicate that its use in these age groups is generally not recommended.


Q: Are there different forms or strengths of Xiety available?

A: Yes, Xiety (Buspirone) is available as an oral tablet. According to official labeling, it is manufactured in several tablet strengths, commonly including 5 mg, 7.5 mg, 10 mg, 15 mg, and 30 mg.


Q: Is it necessary to stop taking Xiety slowly?

A: Regulatory information notes that Xiety should not be stopped abruptly. A gradual reduction in dosage, often called tapering, is usually recommended to help reduce the chance of certain effects associated with discontinuation.


Q: Does Xiety cause weight gain in most people who take it?

A: Official clinical trial data lists weight changes (either weight gain or loss) as an uncommon or less common side effect reported in clinical trials. This means it was not among the most frequently reported issues for patients taking the medication.


Q: Is it common to feel tired or dizzy when starting Xiety?

A: Yes, regulatory documents list dizziness and drowsiness/fatigue as common side effects. Clinical data shows these effects occurred in 1% to 10% of patients during trials, often when first starting the medication.


Q: Is Xiety considered a controlled substance?

A: No, Xiety (Buspirone) is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or similar international bodies. This differs from other medications sometimes prescribed for anxiety.


Q: Can Xiety be used by people who are elderly?

A: While the drug is not generally excluded for the elderly, official guidance notes that caution is needed and dose adjustments may be required for individuals with severe liver or kidney impairment. These conditions may be more common in older adults.


Q: Is Xiety safe to take for long periods of time?

A: Xiety is officially approved for the management of anxiety disorders or for the short-term relief of anxiety symptoms. For use extending beyond a short term, the regulatory label notes that a reassessment of therapeutic benefit is necessary.


Q: Do I need a special blood test or check-up while taking Xiety?

A: Regulatory information indicates that a physician may order certain laboratory tests to check how a patient is responding to the medication. These tests help monitor the patient's general health during treatment.


Q: Can taking Xiety lead to dependency or addiction?

A: Official labeling and regulatory data indicate that Xiety has a low risk for dependence and addiction. This factor distinguishes it from some other types of anxiety medications.


Q: What percentage of people experience side effects from Xiety?

A: Clinical trial data provides frequency ranges for various side effects. For instance, the most common side effects like dizziness and headache were reported by 10% or more of patients in studies.


Q: Are the side effects of Xiety permanent?

A: Regulatory information and clinical experience suggest that most common side effects, such as initial dizziness or nausea, often improve or resolve as the body adjusts to the medication over the first few weeks of treatment.


Q: Is it normal to have vivid dreams or sleep changes with Xiety?

A: Yes, sleep disturbances are listed in the official product information. This includes symptoms such as insomnia and vivid dreams or dream disturbances, which are considered common side effects (occurring in 1% to 10% of patients).


Q: How does Xiety affect a person's ability to drive or operate machinery?

A: Official warnings indicate that Xiety may impair thinking or reactions. For this reason, official labeling recommends caution regarding driving or operating machinery until the individual knows how the drug affects them.


Q: Does alcohol interact dangerously with Xiety?

A: Regulatory information states that alcohol consumption should be avoided while taking this medication. Alcohol can increase the risk of side effects, such as dizziness and drowsiness.


Q: Can Xiety be taken with over-the-counter pain relievers like ibuprofen?

A: Official labeling generally recommends that patients review all prescription and over-the-counter (OTC) medicines with a healthcare professional. This is because certain OTC drugs can increase drowsiness or affect how Xiety is processed in the body.


Q: What are the serious but rare side effects of Xiety?

A: Official labeling outlines serious, though rare, side effects, which have included confusion, chest pain, and incoordination. The risk of Serotonin Syndrome is also a listed concern when used with other serotonin-altering drugs.


Q: When was Xiety first approved by the FDA or similar agency?

A: Regulatory history indicates that the active ingredient in Xiety, Buspirone, was first approved by the U.S. FDA in 1986.


Q: Is it true that Xiety can cause changes in mood or behavior?

A: Side effects in the psychiatric category (1% to 10%) include excitement, nervousness, anger/hostility, and confusion, and depression. These are based on findings from clinical trials.


Q: Does Xiety interact with herbal supplements like St. John's Wort?

A: Official product information notes that certain herbal products and supplements may interact with how Xiety is processed in the body. Therefore, the official label recommends that all supplements be reviewed by a healthcare professional.


Q: Can people with high blood pressure take Xiety?

A: While the presence of high blood pressure is not a general contraindication, the official label does list both hypotension (low blood pressure) and hypertension (high blood pressure) as uncommon side effects reported in clinical trials.


Q: Is Xiety safe to use during pregnancy or while breastfeeding?

A: Regulatory information notes that there are no controlled studies on the use of Xiety in pregnant women. The drug is also known to be excreted into human milk. The decision is subject to careful medical assessment when used during pregnancy or breastfeeding.


Q: Does Xiety affect sexual function?

A: Official product information lists changes in sexual function as a possible side effect. This includes decreased or increased libido as an uncommon effect. Rare side effects include delayed ejaculation or impotence.


Q: Does Xiety affect your heart rate or blood pressure?

A: Tachycardia/palpitations (fast/pounding heartbeat) and chest pain are listed as common side effects (1% to 10%) in regulatory data. Changes in blood pressure are also listed.


Q: Is it normal for Xiety to make symptoms worse before they get better?

A: Some patients have reported increased anxiety or nervousness (1% to 10%) as a common side effect when starting the medication. This observation is based on regulatory clinical trial data.


Q: Does Xiety interact with common allergy medications?

A: Official warnings state that combining Xiety with other medicines that cause central nervous system (CNS) depression may require caution. Certain antihistamines or allergy medications fall into this group and may increase the drowsiness associated with Xiety.


Q: How long does Xiety stay in the body after the last dose?

A: Pharmacokinetic data shows that Xiety has a relatively short half-life, which is the time it takes for half of the dose to be eliminated from the body. This is typically about 2 to 3 hours.


Q: Are there any specific foods or drinks to avoid while taking Xiety?

A: Official patient information notes that grapefruit or grapefruit juice consumption should be avoided. Grapefruit can interfere with how the body processes the medication, potentially increasing the amount of Xiety in the blood and leading to a higher risk of side effects.


Q: Are there specific medical conditions that make someone ineligible for Xiety?

A: Regulatory documents identify a known allergy to the drug as a contraindication. Increased caution and potential dose adjustments are necessary for patients with severe liver (hepatic) or kidney (renal) disease.

How should Xiety be stored and disposed of?

How to Store and Dispose of Xiety?

Xiety (Buspirone hydrochloride) tablets must be stored according to official regulatory specifications to maintain product quality and ensure safety.

Storage Conditions

Requirement Condition
Temperature Store at room temperature, not above 25 C.
Protection Keep away from light, moisture, and excess heat.
Container Keep in the original container and keep the container tightly closed.

The medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Xiety should be disposed of via a drug take-back program or an authorized collection site. This medication is not on the FDA's flush list and should not be flushed down the toilet. If a take-back program is unavailable, mix the tablets with an undesirable substance, seal the mixture, and discard it in the household trash, in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xiety found in:

A-Z Index: